Oncogenic Mutant P53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition Via Oxidative Stress-Dependent Induction of Mitochondrial Apoptosis

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2024 Sep 20

PMID 39302104

Authors

Kranthi Kumar Chougoni

Victoria Neely

Boxiao Ding

Eziafa Oduah

Vianna T Lam

Bin Hu

Jennifer E Koblinski

Bradford E Windle

Swati Palit Deb

Sumitra Deb

Jorge J Nieva

Senthil K Radhakrishnan

Hisashi Harada

Steven R Grossman

Affiliations

Soon will be listed here.

Abstract

NSCLC is the leading cause of cancer death due, in part, to a lack of active therapies in advanced disease. We demonstrate that combination therapy with a proteasome inhibitor, BH3-mimetic, and chemotherapy is an active precision therapy in NSCLC cells and tumors expressing Onc-p53 alleles.

References

Manasanch E, Orlowski R . Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017; 14(7):417-433. PMC: 5828026. DOI: 10.1038/nrclinonc.2016.206. View

Rojo de la Vega M, Chapman E, Zhang D . NRF2 and the Hallmarks of Cancer. Cancer Cell. 2018; 34(1):21-43. PMC: 6039250. DOI: 10.1016/j.ccell.2018.03.022. View

Guang M, Kavanagh E, Dunne L, Dowling P, Zhang L, Lindsay S . Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. Cancers (Basel). 2019; 11(1). PMC: 6356294. DOI: 10.3390/cancers11010066. View

Robak P, Robak T . Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. Drugs R D. 2019; 19(2):73-92. PMC: 6544598. DOI: 10.1007/s40268-019-0269-9. View

Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D . The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2005; 107(1):257-64. DOI: 10.1182/blood-2005-05-2091. View

Aggarwal V, Tuli H, Varol A, Thakral F, Yerer M, Sak K . Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. Biomolecules. 2019; 9(11). PMC: 6920770. DOI: 10.3390/biom9110735. View

Chua A, Thaarun T, Yang H, Lee A . Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence. Health Sci Rep. 2023; 6(11):e1443. PMC: 10643516. DOI: 10.1002/hsr2.1443. View

Mogi A, Kuwano H . TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol. 2011; 2011:583929. PMC: 3035360. DOI: 10.1155/2011/583929. View

Alvarado-Ortiz E, de la Cruz-Lopez K, Becerril-Rico J, Sarabia-Sanchez M, Ortiz-Sanchez E, Garcia-Carranca A . Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches. Front Cell Dev Biol. 2021; 8:607670. PMC: 7905058. DOI: 10.3389/fcell.2020.607670. View

10.

Jones C, Tepe J . Proteasome Activation to Combat Proteotoxicity. Molecules. 2019; 24(15). PMC: 6696185. DOI: 10.3390/molecules24152841. View

11.

Du Z, Zhang H, Meng X, Guan Y, Wang H . Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells. BMC Cancer. 2009; 9:56. PMC: 2666756. DOI: 10.1186/1471-2407-9-56. View

12.

Lakhani N, Rasco D, Wang H, Men L, Liang E, Fu T . First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2023; 30(3):506-521. DOI: 10.1158/1078-0432.CCR-23-1525. View

13.

Narita T, Ri M, Masaki A, Mori F, Ito A, Kusumoto S . Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy. Blood Cancer J. 2015; 5:e373. PMC: 4735074. DOI: 10.1038/bcj.2015.98. View

14.

Ano Bom A, Rangel L, Costa D, de Oliveira G, Sanches D, Braga C . Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J Biol Chem. 2012; 287(33):28152-62. PMC: 3431633. DOI: 10.1074/jbc.M112.340638. View

15.

Skoulidis F, Heymach J . Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019; 19(9):495-509. PMC: 7043073. DOI: 10.1038/s41568-019-0179-8. View

16.

Auner H, Moody A, Ward T, Kraus M, Milan E, May P . Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. PLoS One. 2013; 8(9):e74415. PMC: 3775786. DOI: 10.1371/journal.pone.0074415. View

17.

Bellezza I, Giambanco I, Minelli A, Donato R . Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res. 2018; 1865(5):721-733. DOI: 10.1016/j.bbamcr.2018.02.010. View

18.

Craxton A, Butterworth M, Harper N, Fairall L, Schwabe J, Ciechanover A . NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1. Cell Death Differ. 2012; 19(9):1424-34. PMC: 3422467. DOI: 10.1038/cdd.2012.16. View

19.

Cordani M, Butera G, Pacchiana R, Masetto F, Mullappilly N, Riganti C . Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells. Biomolecules. 2020; 10(3). PMC: 7175157. DOI: 10.3390/biom10030361. View

20.

Davies A, Chansky K, Lara Jr P, Gumerlock P, Crowley J, Albain K . Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol. 2008; 4(1):87-92. PMC: 3024911. DOI: 10.1097/JTO.0b013e3181915052. View